Galderma Laboratories, L.P. is initiating six new Phase III and IV U.S. aesthetic clinical trials.

The six newly initiated studies include three pivotal trials evaluating XpresHAn Technology products; two studies for Dysport evaluating patient satisfaction and duration; and one study focusing on the unique properties of Sculptra Aesthetic (injectable poly-L-lactic acid).

The company's R&D expansion also includes a significant increase in the number of women selected as clinical investigators. Since Galderma acquired the U.S. rights to Dysport (abobotulinumtoxinA), Restylane, and SculptraAesthetic in 2014, the number of female clinical investigators in company-sponsored trials has more than doubled.

"I am excited to partner with a company like Galderma who is continuing to invest in the aesthetics market and being thoughtful about the composition of their clinical trial investigator group," said Sue Ellen Cox, MD, founder and medical director of Aesthetic Solutions, Chapel Hill, NC and a primary investigator for Galderma's new trials.